vimarsana.com

Latest Breaking News On - சாண்டர் வேன் டெவெண்டேர் - Page 1 : vimarsana.com

7 top-performing Dutch venture capital funds by IRR

7 top-performing Dutch venture capital funds by IRR
pitchbook.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pitchbook.com Daily Mail and Mail on Sunday newspapers.

Norway
Germany
United-states
Netherlands
United-kingdom
Singapore
Montreal
Quebec
Canada
Brighton
Brighton-and-hove
Oslo

VectorY Raises €31 Million in Seed Financing to Develop Next-Generation Gene Therapies Aimed at Muscular and CNS Disorders

VectorY Raises €31 Million in Seed Financing to Develop Next-Generation Gene Therapies Aimed at Muscular and CNS Disorders
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Germany
Netherlands
Singapore
Naarden
Noord-holland
Amsterdam
Dutch
Marco-boorsma
Sanofi-genzyme
Eli-lilly
Carlo-incerti
Sander-van-deventer

VectorY Raises €31M in Seed Funding

VectorY Raises €31M in Seed Funding
finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.

Netherlands
Amsterdam
Noord-holland
Marco-boorsma
Sanofi-genzyme
Eli-lilly
Carlo-incerti
Sander-van-deventer
Alexander-vos
Vectory-therapeutics
Amsterdam-science-park
Chief-medical-officer

Forbion invests USD 2.3M in seed financing of CoviCept Therapeutics, Inc.

Posted on 7468 Forbion, a leading European life sciences venture capital firm, today announces a $2.3m seed investment in newly formed CoviCept Therapeutics, Inc. (“CoviCept”), a California-based company that is developing a small molecule that inhibits the replication of SARS-CoV-2 (COVID-19) and other RNA viruses. CoviCept’s lead molecule has a unique mechanism of action that is based on interference of a host cell protein and is therefore expected to have a low risk of viral resistance. It has been demonstrated to inhibit SARS-CoV-2 replication in a relevant mammalian model at a clinically relevant dose. A manufacturing process for the lead compound has been established and it has demonstrated good bioavailability and safety in humans in phase 1 studies.

Germany
California
United-states
San-diego
Netherlands
University-of-california-san-diego
Singapore
Dutch
Philip-gordts
Jeffrey-esko
Sander-van-deventer-forbion
Sam-tsimikas

vimarsana © 2020. All Rights Reserved.